This article has Open Peer Review reports available.
Association between serum selenium level and type 2 diabetes mellitus: a non-linear dose–response meta-analysis of observational studies
© Wang et al. 2016
Received: 5 January 2016
Accepted: 26 April 2016
Published: 4 May 2016
The association between serum selenium levels and type 2 diabetes mellitus (T2DM) is controversial. We performed a systematic review and non-linear dose–response meta-analysis of observational studies to investigate the association in the present study.
A comprehensive literature search was conducted using MEDLINE and EMBASE databases. A pooled odds ratio (OR) and related 95 % confidence interval (95 % CI) for T2DM between the highest and lowest serum selenium categories, and a non-linear dose–response relationship between selenium and T2DM were estimated.
A total of five studies (of 13,460 participants) were identified as meeting the inclusion criteria. The pooled OR indicated that there was a significantly higher prevalence of T2DM in the highest category of blood selenium compared with the lowest (OR = 1.63, 95 % CI: 1.04–2.56, P = 0.033). Moreover, a significant non-linear dose–response relationship was observed between serum selenium levels and T2DM (P < 0.001). Serum selenium levels were positively associated with T2DM in populations with relatively low serum selenium levels (<97.5 μg/l) and those with high serum selenium levels (>132.5 μg/l).
The positive association between serum selenium levels and T2DM existed in populations with relatively low levels and high levels of serum selenium, indicating a likely U-shaped non-linear dose–response relationship between serum selenium and T2DM.
Selenium is one of the most essential trace elements for human health. It functions as a redox center as part of the family of selenium-dependent glutathione peroxidases (GPx), transforming hydrogen peroxide and damaging lipid and phospholipid hydroperoxides into harmless products [1–3]. It is also a basic component of selenoproteins, which are a group of critically important enzymes . In its protective role against oxidative stress, selenium has drawn increasing attention for preventing type 2 diabetes mellitus (T2DM), cardiovascular disease, cancer, and other chronic diseases [4–6]. Low selenium levels are thought to contribute to disease etiology, or may be a consequence of disease that aggravates the condition further .
T2DM is the most common form of diabetes, and is caused by a progressive insulin secretory defect against a background of insulin resistance . Its relationship with oxidative stress may reflect the excess levels of reactive oxygen species in hyperglycemia. Oxidative stress has a huge impact on the etiology, pathogenesis, and complications of T2DM [8, 9]. In view of the protective function of selenium against oxidative stress, selenium might be expected to play a protective role against T2DM. However, the relationship between selenium and T2DM is highly complex. The over-expression of GPx in islets may protect pancreatic β cells from oxidative stress, stimulate pancreatic β cell gene expression, and improve islet function [10–12]. Conversely, high selenium concentrations in the human body may interfere with insulin signaling, which is critical to the regulation of glucose levels and the prevention of diabetes [13, 14].
Many researchers have investigated the effects of blood selenium levels on T2DM, but the conclusions are controversial. Some studies report that blood selenium is negatively associated with T2DM [15–23], while others indicate a positive correlation [24–28]. Meanwhile, no significant association is documented by other reports [29–34]. Because of this complicated relationship between selenium and T2DM, we hypothesized that it might not be linear. Additionally, the selenium status and intake vary widely in different parts of the world , which might cause the inconsistencies observed in study outcomes.
A previous review article  suggested that there might be no standard or specific definition for serum or plasma selenium deficiencies. However, recommendations for dietary selenium intake are available, advising an average of 60 μg per day for men and 53 μg per day for women . Several previous studies indicated that individuals with serum or plasma selenium concentrations of 122 μg/L or higher should not supplement with selenium [36, 37]. Conversely, those with serum or plasma selenium concentrations lower than 122 μg/L could benefit from increased levels (up to 130–150 μg/L), which would reduce their mortality . However, these findings were based on qualitative estimations, and the relationship between serum selenium levels and T2DM remains unclear.
Therefore, the objective of the present research was to comprehensively review the evidence on the association between serum selenium levels and T2DM by conducting a non-linear dose–response meta-analysis of observational studies.
This meta-analysis was conducted following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. MEDLINE and EMBASE databases were searched in September 2015 to identify relevant observational studies that investigated the relationship between blood selenium levels and T2DM. Search key words included “diabetes mellitus”, “T2DM”, “NIDDM”, and “selenium”. The specific search strategies are listed in Additional file 1: Appendix 1.
Two researchers independently reviewed all citations and abstracts generated by the literature search. Qualified studies were subsequently examined for inclusion. Each researcher independently assessed the full texts in a blinded and standardized manner using a customized form to determine whether all inclusion criteria were met. Disagreements were resolved by discussion to reach a consensus.
Studies that met the following criteria were included: 1) observational comparative studies relating to the association between blood selenium levels and T2DM; 2) patients diagnosed with confirmed T2DM; 3) the exposure of interest was serum selenium levels, and at least three quantitative categories of selenium levels were classified; 4) the selenium level for each response category was provided or could be calculated; 5) the study reported numbers of cases and controls for each serum selenium category; and 6) full research articles. Exclusion criteria were: 1) patients with type 1 diabetes mellitus or gestational diabetes; 2) randomized controlled trials investigating the effect of selenium supplementation on T2DM; 3) review articles; 4) in vitro studies and animal experiments; and 5) short reports or meeting abstracts.
Data extraction and quality assessment
The following background information was extracted from the included studies: first author, publication year, country, study design, setting, study population, sample size, basic characteristics of participants (age, sex, and body mass index), and selenium classification. Data on the number of cases and participants in different selenium categories, and the odds ratios (ORs) of incidence/prevalence of T2DM between the highest and the lowest selenium category were extracted for analysis.
The methodological quality of included studies was evaluated by the Newcastle–Ottawa Scale (NOS) , which was developed to assess the quality of non-randomized studies based on three broad perspectives: selection of the study groups; comparability among different groups; and the ascertainment of either the exposure or outcome of interest. The total NOS score ranged from 0 to 9 based on the assessment items. Studies scoring higher than 6 were considered to have a high methodological quality.
The association between blood selenium levels and T2DM was evaluated by the pooled OR and related 95 % confidence interval (95 % CI) for T2DM between the highest and lowest selenium categories. The heterogeneity of effect size across studies was tested by the Q statistic (P < 0.05 was considered heterogeneous) or I2 statistic (I2 > 50 % was considered heterogeneous). The random effects model was used if significant heterogeneity was detected among studies; otherwise, the fixed effects model was applied. Sensitivity analysis was conducted to examine the influence of specific exclusion criteria on the overall effect size. Begg’s tests  and funnel plots were performed to assess publication bias.
A two-stage random effects dose–response meta-analysis was conducted to investigate the potential non-linear dose–response relationship between blood selenium levels and T2DM . First, a restricted cubic splines model with four knots at percentiles 5, 35, 65, and 95 % of the distribution was adopted using generalized least squares regression. Then, the restricted maximum likelihood method in a random effects meta-analysis was adopted to calculate the pooled study-specific estimates [42–44]. The median or mean selenium concentration for each category was assigned to each corresponding OR with 95 % CI. When only the range of the selenium concentration was reported, the mid-point of the range was adopted to represent the category. When the category was open-ended, we assumed the open-ended interval length was the same as the adjacent interval [45, 46].
Statistical analyses were performed using STATA version 11.0 (StataCorp LP, College Station, TX). P < 0.05 was considered to be statistically significant.
The association between blood selenium level and T2DM were evaluated by a pooled OR and related 95 % confidence interval (95 % CI) for T2DM between the highest and the lowest selenium category. The heterogeneity of effect size across studies was tested by Q statistic (p < 0.05 was considered heterogeneous) or I2 statistic (I2 > 50 % was considered heterogeneous). If there was a significant heterogeneity among studies, the random-effects model was used; otherwise, the fixed-effects model was applied. A sensitivity analysis was conducted to examine the influence of specific exclusion criteria on the overall effect sizes. Begg’s tests  and funnel plot was performed to assess the publication bias.
For the potential non-linear dose–response relationship between blood selenium level and T2DM, a 2-stage, random effects, dose–response meta-analysis was conducted . Firstly, restricted cubic splines model with four knots at percentiles 5, 35, 65 and 95 % of the distribution was adopted by using generalized least squares regression. Then the restricted maximum likelihood method in a random-effects meta-analysis was adopted to calculate the pooled study-specific estimates [42–44]. The median or mean selenium concentration for each category was assigned to each corresponding ORs with 95 % CI. When only range of selenium concentration was reported, the mid-point of the range was adopted for representing the category. When the category was open-ended, we assumed the open-ended interval length to be the same as the adjacent interval [45, 46].
Statistical analyses were performed using STATA version 11.0 (StataCorp LP, College Station, Texas). P < 0.05 was considered to be statistically significant.
Characteristics of studies included in the meta-analysis
First author, year and country
Setting, study population
Sample size (n)
BMI (kg/m2), mean
Selenium classification (range)
Definition of T2DM
Longitudinal study (data were extracted from baseline)
Community, rural municipality of inhabitants in the south-east of Sweden.
Quartiles: <57.2, 57.2–67.1, 67.1–76.1, >76.1 μg/l
Community, NHANES III participants
Quintiles: <111.62, 111.62–120.17, 120.18–128.25, 128.26–137.65, >137.65 μg/l
Defined as a fasting plasma glucose ≥ 126 mg/dl, a self-report of a physician diagnosis of diabetes, or current use of insulin or oral hypoglycemic medication
Community, civilian non-institutionalized U.S. population from NHANES 2003–2004
Quartiles: <124, 124–133, 134–146, >146 μg/l
Defined as the presence of either a self-report of current use of hypoglycemic agents or insulin or fasting plasma glucose ≥ 126 mg/dL.
Longitudinal study (data were extracted from baseline)
Community, male workforce of the Olivetti factories in Pozzuoli (Naples) and Marcianise (Caserta), Southern Italy.
Tertiles: <69.7, 69.7–82.6, > 82.6 μg/l
Defined as a fasting blood glucose level ≥ 126 mg/dL or anti-diabetic therapy.
Community, all 50-year-old men living in Uppsala County, Sweden.
Tertiles: 61.4, 75.1, 91.1 μg/la
Defined by elevated fasting glucose levels and/or use of anti-diabetic medicine. Elevated glucose levels were assessed as fasting blood glucose ≥6.1 mmol/l at the age 60 years’ examination (equals ≥7.0 mmol/l of plasma glucose) and fasting plasma glucose ≥ 7.0 mmol/l at age 70 years and age 77 years
Methodological quality assessment according to Newcastle-Ottawa Scale (NOS)
Adequate definition of case/exposed cohort
Representativeness of the cases/ exposed cohort
Selection of Controls
Definition of Controls
Comparability of cases and controls (worth 2 points)
Ascertainment of exposure/outcome
Same method of ascertainment for cases and controls/long enough for outcomes to occur
OR for T2DM between different serum selenium categories
Non-linear dose–response relationship between blood selenium and T2DM
To the best of our knowledge, this is the first systematic review and dose–response meta-analysis examining the association between serum selenium levels and T2DM based on previous observational studies. We found a significantly higher prevalence of T2DM in the highest category of blood selenium compared with the lowest, and serum selenium levels were positively associated with T2DM in populations with relatively low (<97.5 μg/l) or high serum selenium levels (>132.50 μg/l).
Previous evidence about the relationship between selenium and T2DM is conflicting. Some studies claim that patients with T2DM have significantly lower selenium concentrations compared with healthy subjects [15–23]. Antioxidants in non-diabetic individuals can mitigate free radical-mediated oxidative stress, but in the chronic hyperglycemia state, increased free radical production may lead to the overconsumption of chain-breaking antioxidants, elevated lipid peroxidation, and enhanced oxidative stress . Selenium is believed to be one of the most important antioxidant nutrients in the human body, and selenoproteins have a protective effect against oxidative stress and inflammation [5, 8]. However, the lower selenium status measured in T2DM populations of some case–control studies might be caused by the disease and its association with inflammation. Other previous studies have suggested that the inflammatory response decreases the expression of selenoprotein P and reduces plasma selenium concentrations [48, 49].
Conversely, some studies report that patients with T2DM have higher selenium concentrations compared with healthy subjects, and that blood selenium levels positively correlate with T2DM [24–28]. The over-expression of GPx1 in transgenic mice was found to lead to the development of insulin resistance, hyperglycemia, hyperinsulinemia, and obesity. After knocking out GPx1, both insulin-induced glucose uptake and insulin sensitivity were improved [50–52]. This was explained by GPx1 removing hydrogen peroxide, a second messenger in the insulin signaling cascade, and insulin binding to its receptor . The same correlation was also observed between increased erythrocyte GPx1 activity and mild insulin resistance in pregnant women . Another selenoprotein, SeP, was also shown to be related to insulin resistance by aggravating insulin resistance through impairing insulin signaling . Studies have revealed a significantly positive association between SeP and fasting plasma glucose in Japanese and Korean populations [54, 55]. Moreover, in an earlier study, we found a significant positive correlation between dietary selenium intake and the prevalence of diabetes .
Previous review articles have suggested that the association between selenium and T2DM is U-shaped, such that selenoprotein levels both below and above the physiological range are possible risk factors for T2DM [5, 8, 12]. This estimation is consistent with our non-linear dose–response analysis. We observed a moderately positive association between selenium and T2DM in individuals with relatively low levels of serum selenium (<100 μg/l), a non-significant association between selenium and T2DM in individuals with middle levels of serum selenium (100–130 μg/l), and a strongly positive association in individuals with relatively high levels of serum selenium (>130 μg/l). Stranges et al.  concluded that selenium supplementation does not prevent T2DM, but may instead increase the disease risk in populations with a median serum selenium level of 136 μg/l. Another study suggested that both high and low expression levels of GPx1 and other related selenoproteins are harmful because of their effects on insulin resistance and hyperglycemia .
The present study has several strengths. It is the first meta-analysis to perform a systematic and quantitative analysis of the association between serum/plasma selenium levels and T2DM. Several review articles [5, 8, 12] have attempted to examine this relationship, but none performed a quantitative analysis. Second, this study showed a specific non-linear dose–response relationship between serum selenium levels and T2DM. However, the limitations of the present study should also be acknowledged. The number of studies included in the analysis was very limited. Second, the shortage of prospective cohort studies could explain the causal relationship between selenium and T2DM. Therefore, future prospective cohort studies are needed to further explore this relationship. Finally, because glucose levels vary greatly in patients with T2DM, direct correlations of selenium levels with glucose levels would provide us with relevant information. Unfortunately, only two studies [27, 32] have reported these data. Additionally, the search strategy and included studies required for these analyses would differ from those of the present meta-analysis. Thus, this would best be examined as part of a future study.
In conclusion, we detected a positive association between serum selenium levels and T2DM in populations with relatively low and high serum levels of selenium, revealing a U-shaped non-linear dose–response relationship between serum selenium and T2DM.
This work was supported by the Fundamental Research Funds for the Central Universities of Central South University (2014zzts070), the Hunan Provincial Innovation Foundation for Postgraduate (CX2014B096).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Rayman MP. The importance of selenium to human health. Lancet. 2000;356(9225):233–41.View ArticlePubMedGoogle Scholar
- Allan CB, Lacourciere GM, Stadtman TC. Responsiveness of selenoproteins to dietary selenium. Annu Rev Nutr. 1999;19:1–16.View ArticlePubMedGoogle Scholar
- Diplock AT. Antioxidants and disease prevention. Mol Aspects Med. 1994;15(4):293–376.View ArticlePubMedGoogle Scholar
- Neve J. Selenium as a risk factor for cardiovascular diseases. J Cardiovasc Risk. 1996;3(1):42–7.View ArticlePubMedGoogle Scholar
- Rayman MP. Selenium and human health. Lancet. 2012;379(9822):1256–68.View ArticlePubMedGoogle Scholar
- Steinbrenner H, Sies H. Protection against reactive oxygen species by selenoproteins. Biochim Biophys Acta. 2009;1790(11):1478–85.View ArticlePubMedGoogle Scholar
- American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(1):S14–80.View ArticleGoogle Scholar
- Rayman MP, Stranges S. Epidemiology of selenium and type 2 diabetes: can we make sense of it? Free Radic Biol Med. 2013;65:1557–64.View ArticlePubMedGoogle Scholar
- Robertson RP, Harmon JS. Pancreatic islet beta—cell and oxidative stress: the importance of glutathione peroxidase. Febs Lett. 2007;581(19):3743–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Campbell SC, Aldibbiat A, Marriott CE, Landy C, Ali T, Ferris WF, Butler CS, Shaw JA, Macfarlane WM. Selenium stimulates pancreatic beta-cell gene expression and enhances islet function. Febs Lett. 2008;582(15):2333–7.Google Scholar
- Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681–7.Google Scholar
- Rocourt CR, Cheng WH. Selenium supranutrition: are the potential benefits of chemoprevention outweighed by the promotion of diabetes and insulin resistance? Nutr. 2013;5(4):1349–65.Google Scholar
- Goldstein BJ, Mahadev K, Wu X. Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes. 2005;54(2):311–21.View ArticlePubMedPubMed CentralGoogle Scholar
- Steinbrenner H, Speckmann B, Pinto A, Sies H. High selenium intake and increased diabetes risk: experimental evidence for interplay between selenium and carbohydrate metabolism. J Clin Biochem Nutr. 2011;48(1):40–5.View ArticlePubMedGoogle Scholar
- Joshi U, Raut P, Agrawal S, Patra P, Maheshwari B, Apurb M, TC D. Evaluation of serum selenium level in patients with uncomplicated diabetes mellitus, Raipur, India. J Clin Diagn Res. 2011;5:70–3.Google Scholar
- Kljai K, Runje R. Selenium and glycogen levels in diabetic patients. Biol Trace Elem Res. 2001;83(3):223–9.View ArticlePubMedGoogle Scholar
- Kornhauser C, Garcia-Ramirez JR, Wrobel K, Perez-Luque EL, Garay-Sevilla ME, Wrobel K. Serum selenium and glutathione peroxidase concentrations in type 2 diabetes mellitus patients. Prim Care Diabetes. 2008;2(2):81–5.View ArticlePubMedGoogle Scholar
- Navarro-Alarcon M, Lopez-G DLSH, Perez-Valero V, Lopez-Martinez C. Serum and urine selenium concentrations as indicators of body status in patients with diabetes mellitus. Sci Total Environ. 1999;228(1):79–85.View ArticlePubMedGoogle Scholar
- Salem M, Kholoussi S, Kholoussi N, Fawzy R. Malondialdehyde and trace element levels in patients with type 2 diabetes mellitus. Arch hell med. 2011;28(1):83–8.Google Scholar
- Serdar MA, Bakir F, Haşimi A, Çelik T, Akin O, Kenar L, Aykut O, Yildirimkaya M. Trace and toxic element patterns in nonsmoker patients with noninsulin-dependent diabetes mellitus, impaired glucose tolerance, and fasting glucose. Int j diabetes dev ctries. 2009;29(1):35.Google Scholar
- Thomas B, Ramesh A, Suresh S, Prasad BR. A comparative evaluation of antioxidant enzymes and selenium in the serum of periodontitis patients with diabetes mellitus type 2. Contemp clin dent. 2013;4(2):176.View ArticlePubMedPubMed CentralGoogle Scholar
- Whiting PH, Kalansooriya A, Holbrook I, Haddad F, Jennings PE. The relationship between chronic glycaemic control and oxidative stress in type 2 diabetes mellitus. Br J Biomed Sci. 2008;65(2):71–4.View ArticlePubMedGoogle Scholar
- Zhao C, Wang H, Zhang J, Feng L. [Correlations of trace elements, glucose and body compositions in type 2 diabetics]. Wei Sheng Yan Jiu. 2008;37(5):600–1. 605.PubMedGoogle Scholar
- Agte VV, Tarwadi KV. Combination of diabetes and cataract worsens the oxidative stress and micronutrient status in Indians. Nutrition. 2008;24(7–8):617–24.View ArticlePubMedGoogle Scholar
- Bleys J, Navas-Acien A, Guallar E. Serum selenium and diabetes in U.S. adults. Diabetes Care. 2007;30(4):829–34.View ArticlePubMedGoogle Scholar
- Flores CR, Puga MP, Wrobel K, Garay SM, Wrobel K. Trace elements status in diabetes mellitus type 2: possible role of the interaction between molybdenum and copper in the progress of typical complications. Diabetes Res Clin Pract. 2011;91(3):333–41.View ArticlePubMedGoogle Scholar
- Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, Guallar E. Serum selenium concentrations and diabetes in U.S. Adults: national health and nutrition examination survey (NHANES) 2003–2004. Environ Health Perspect. 2009;117(9):1409–13.View ArticlePubMedPubMed CentralGoogle Scholar
- Stranges S, Galletti F, Farinaro E, D’Elia L, Russo O, Iacone R, Capasso C, Carginale V, De Luca V, Della VE et al. Associations of selenium status with cardiometabolic risk factors: an 8-year follow-up analysis of the Olivetti heart study. Atherosclerosis. 2011;217(1):274–8.Google Scholar
- Coudray C, Roussel AM, Mainard F, Arnaud J, Favier A. Lipid peroxidation level and antioxidant micronutrient status in a pre-aging population; correlation with chronic disease prevalence in a French epidemiological study (Nantes, France). J Am Coll Nutr. 1997;16(6):584–91.PubMedGoogle Scholar
- Ekmekcioglu C, Prohaska C, Pomazal K, Steffan I, Schernthaner G, Marktl W. Concentrations of seven trace elements in different hematological matrices in patients with type 2 diabetes as compared to healthy controls. Biol Trace Elem Res. 2001;79(3):205–19.View ArticlePubMedGoogle Scholar
- Forte G, Bocca B, Peruzzu A, Tolu F, Asara Y, Farace C, Oggiano R, Madeddu R. Blood metals concentration in type 1 and type 2 diabetics. Biol Trace Elem Res. 2013;156(1–3):79–90.Google Scholar
- Gao H, Hagg S, Sjogren P, Lambert PC, Ingelsson E, van Dam RM. Serum selenium in relation to measures of glucose metabolism and incidence of type 2 diabetes in an older Swedish population. Diabet Med. 2014;31(7):787–93.View ArticlePubMedGoogle Scholar
- Hughes K, Choo M, Kuperan P, Ong CN, Aw TC. Cardiovascular risk factors in non-insulin-dependent diabetics compared to non-diabetic controls: a population-based survey among Asians in Singapore. Atherosclerosis. 1998;136(1):25–31.View ArticlePubMedGoogle Scholar
- Yerlikaya FH, Toker A, Aribas A. Serum trace elements in obese women with or without diabetes. Indian J Med Res. 2013;137(2):339–45.PubMedPubMed CentralGoogle Scholar
- Rayman MP, Infante HG, Sargent M. Food-chain selenium and human health: spotlight on speciation. Br J Nutr. 2008;100(2):238–53.PubMedGoogle Scholar
- Clark LC, Combs GJ, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276(24):1957–63.Google Scholar
- Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, Cappuccio FP, Ceriello A, Reid ME. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med. 2007;147(4):217–23.Google Scholar
- Bleys J, Navas-Acien A, Guallar E. Serum selenium levels and all-cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med. 2008;168(4):404–10.View ArticlePubMedGoogle Scholar
- Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.View ArticlePubMedGoogle Scholar
- Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose–response relations: examples, an evaluation of approximations, and software. Am J Epidemiol. 2012;175(1):66–73.View ArticlePubMedGoogle Scholar
- Bo Y, Lu Y, Zhao Y, Zhao E, Yuan L, Lu W, Cui L, Lu Q: Association between dietary vitamin C intake and risk of esophageal cancer: A dose–response meta-analysis. Int J Cancer. 2016;138(8):1843-50.Google Scholar
- Gao D, Ning N, Wang C, Wang Y, Li Q, Meng Z, Liu Y, Li Q. Dairy products consumption and risk of type 2 diabetes: systematic review and dose–response meta-analysis. PLoS One. 2013;8(9), e73965.Google Scholar
- Larsson SC, Orsini N, Wolk A. Vitamin B6 and risk of colorectal cancer: a meta-analysis of prospective studies. JAMA. 2010;303(11):1077–83.View ArticlePubMedGoogle Scholar
- Aune D, Saugstad OD, Henriksen T, Tonstad S. Maternal body mass index and the risk of fetal death, stillbirth, and infant death: a systematic review and meta-analysis. JAMA. 2014;311(15):1536–46.View ArticlePubMedGoogle Scholar
- Xu C, Liu T, Kuang X, Zhang Y, Weng H, Zhang C. How to estimate the missing data and transform the effect measure in dose–response meta-analysis. Chin J Evid-based Med. 2015;15(8):984–7.Google Scholar
- Alehagen U, Johansson P, Bjornstedt M, Rosen A, Post C, Aaseth J. Relatively high mortality risk in elderly Swedish subjects with low selenium status. Eur J Clin Nutr. 2015.Google Scholar
- Hesse-Bahr K, Dreher I, Kohrle J. The influence of the cytokines Il-1beta and INFgamma on the expression of selenoproteins in the human hepatocarcinoma cell line HepG2. Biofactors. 2000;11(1–2):83–5.View ArticlePubMedGoogle Scholar
- Nichol C, Herdman J, Sattar N, O’Dwyer PJ, St JOD, Littlejohn D, Fell G. Changes in the concentrations of plasma selenium and selenoproteins after minor elective surgery: further evidence for a negative acute phase response? Clin Chem. 1998;44(8 Pt 1):1764–6.Google Scholar
- Loh K, Deng H, Fukushima A, Cai X, Boivin B, Galic S, Bruce C, Shields BJ, Skiba B, Ooms LM et al. Reactive oxygen species enhance insulin sensitivity. Cell Metab. 2009;10(4):260–72.Google Scholar
- McClung JP, Roneker CA, Mu W, Lisk DJ, Langlais P, Liu F, Lei XG. Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase. Proc Natl Acad Sci U S A. 2004;101(24):8852–7.Google Scholar
- Wang XD, Vatamaniuk MZ, Wang SK, Roneker CA, Simmons RA, Lei XG. Molecular mechanisms for hyperinsulinaemia induced by overproduction of selenium-dependent glutathione peroxidase-1 in mice. Diabetologia. 2008;51(8):1515–24.View ArticlePubMedGoogle Scholar
- Chen X, Scholl TO, Leskiw MJ, Donaldson MR, Stein TP. Association of glutathione peroxidase activity with insulin resistance and dietary fat intake during normal pregnancy. J Clin Endocrinol Metab. 2003;88(12):5963–8.View ArticlePubMedGoogle Scholar
- Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, Kurita S, Ishikura K, Ando H, Takeshita Y, Ota T et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab. 2010;12(5):483–95.Google Scholar
- Yang SJ, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrinol Metab. 2011;96(8):E1325–9.Google Scholar
- Wei J, Zeng C, Gong QY, Yang HB, Li XX, Lei GH, Yang TB. The association between dietary selenium intake and diabetes: a cross-sectional study among middle-aged and older adults. Nutr J. 2015;14:18.Google Scholar
- Labunskyy VM, Lee BC, Handy DE, Loscalzo J, Hatfield DL, Gladyshev VN. Both maximal expression of selenoproteins and selenoprotein deficiency can promote development of type 2 diabetes-like phenotype in mice. Antioxid Redox Signal. 2011;14(12):2327–36.View ArticlePubMedPubMed CentralGoogle Scholar